title: The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
abstract: OBJECTIVE
  Performance status (PS) is an important prognostic factor in advanced ovarian cancer. The purpose of this study was to evaluate the prognostic significance of PS and quality of life (QoL) assessment on progression-free survival (PFS) and overall survival (OS) in patients with advanced ovarian cancer.
  
  
  METHODS
  We studied Canadian patients participating in an intergroup study in ovarian cancer (NCIC-OV10), which randomized patients to receive either standard chemotherapy using cisplatin/cyclophosphamide or cisplatin/paclitaxel chemotherapy. QoL was assessed using the EORTC quality of life questionnaire (QLQ-C30+3). The effects of multiple variables including the relevant clinical variables, PS and QoL scores were analyzed by Cox stepwise regression at baseline and again 3 months after completion of chemotherapy.
  
  
  RESULTS
  At baseline and at 3 months after chemotherapy, there were 151 and 93 patients respectively who completed the QLQ-C30+3 questionnaires. Baseline PS, global QoL score and treatment were independent predictors for both PFS and OS. Baseline cognitive functioning score was also an additional independent predictor for OS. At 3 months after completion of chemotherapy global QoL score, PS and grade were significant independent predictors of OS; however, only physical functioning score, emotional functioning score and tumor grade predicted for PFS.
  
  
  CONCLUSIONS
  Performance status and global quality of life scores at baseline are prognostic factors in advanced ovarian cancer for both PFS and OS. Higher baseline cognitive functioning scores were also associated with improved survival. Global QoL scores at 3 following completion of chemotherapy proved to be of prognostic significance for OS but not PFS.
authors.affiliation: National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada. mcarey@mdanderson.org
authors.forename: M S
authors.initials: MS
authors.lastname: Carey
authors.forename: M
authors.initials: M
authors.lastname: Bacon
authors.forename: D
authors.initials: D
authors.lastname: Tu
authors.forename: L
authors.initials: L
authors.lastname: Butler
authors.forename: A
authors.initials: A
authors.lastname: Bezjak
authors.forename: G C
authors.initials: GC
authors.lastname: Stuart
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology*; D017239:Paclitaxel / Q000008:administration & dosage; D011788:Quality of Life; D015996:Survival Rate
chemical_list: D003520:Cyclophosphamide; D017239:Paclitaxel; D002945:Cisplatin